Categories News Press Releases Archives 2025 June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April March February January 2022 December November October September August June May March February January 2021 December November October September August May April February Aug 17 UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters Read More Share:| | | May 23 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 Read More Share:| | | May 23 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 Read More Share:| | | May 10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Read More Share:| | | Mar 28 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) Read More Share:| | | Mar 26 New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting Read More Share:| | | Mar 07 UCB Completes Acquisition of Zogenix, Inc. Read More Share:| | | Feb 04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Read More Share:| | | Jan 21 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study Read More Share:| | | Jan 19 UCB to acquire Zogenix Read More Share:| | | Pagination First page Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Next page Next › Last page